Vacunas frecuentes utilizadas en América Latina para SARS-COV-2 causante de COVID-19, efectos que producen en grupos poblacionales de 18 a 65 Años

Abstract

The appearance of the outbreak of pneumonia of unknown etiology in the city of Wuhan, Hubei province, China since December 2019, and its accelerated spread not only in the epicenter city but around the world, began one of the viral pandemics with the greatest impact in recent years. worldwide health, social and economic level in the last 100 years, since then, many research teams and companies have devoted their efforts and resources to developing vaccines and treatments against this disease. In this document, information was collected from original scientific articles, reviews and information; reports from different platforms tracking the development of vaccines and official communications by the companies or research institutes that lead the trials of the potential vaccines under study. The clinical trials of the vaccines were carried out in patients between 18 and 65 years of age. majority in phase 3 with a few exceptions, in Latin America, Brazil is the country that has carried out a greater number of clinical trials, the most widely used vaccines in Latin America are Astrazeneca, Sinovac, Pfizer, Cansino, the effects after vaccine report headaches and general malaise and as a positive effect the acquired immunity against SARS-CoV-2, the review carried out leads us to conclude that clinical laboratories provide their service for diagnosis, treatment and control of SARS-CoV-2 but not for assess the immunity produced by vaccinations.